Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10510726" target="_blank" >RIV/00064165:_____/25:10510726 - isvavai.cz</a>
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=wuYX.8s9n2" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=wuYX.8s9n2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41408-025-01444-0" target="_blank" >10.1038/s41408-025-01444-0</a>
Alternative languages
Result language
angličtina
Original language name
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS
Original language description
Lower-risk (LR) myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by ineffective hematopoiesis, abnormal blood cell development, and a relatively low risk of progression to acute myeloid leukemia or death [1]. Anemia is a hallmark of LR-MDS and often leads to chronic red blood cell (RBC) transfusion dependence (TD), which is a reflection of further bone marrow failure, increased disease burden, and shortened survival ( ~ 3–9 years) [1, 2]. These patients present with a clinical challenge, in that the primary therapeutic goal is to improve the cytopenias and manage their symptoms (typically through supportive care and targeted pharmacotherapeutics) rather than controlling the malignant hematopoiesis [3,4,5]. There is an unmet need for improvements in therapies for LR-MDS that can target the underlying cause of the disease.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood Cancer Journal
ISSN
2044-5385
e-ISSN
2044-5385
Volume of the periodical
15
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
4
Pages from-to
217
UT code for WoS article
001651935000002
EID of the result in the Scopus database
2-s2.0-105026349169